obesity drug news today october 2025 glp-1 Agonists Weight Loss Drugs Market Report, 2025-2030 WHO Decision Recognizing Obesity as

The weight loss achieved varies by specific medication and dose: semaglutide 2.4 mg (Wegovy) produces approximately 15% weight loss, tirzepatide (Zepbound) up to 15-22%, and liraglutide 3 mg (Saxenda) about 5-8%

Weight-loss medications like GLP-1 are changing lives, but they also bring real challenges: Appetite loss Protein deficiency Nausea & bloating Muscle loss Fatigue Nutritional imbalance In the U.S., an entire industry has already formed around supporting these patients

References Paccou, J

SGLT2 inhibitors remove glucose through urine, which increases calorie loss and can mimic a state of fasting

At least 12 other states cover GLP-1s for obesity treatment